- Home
- IMRN vs BTAI Comparison
IMRN vs BTAI Comparison
Compare IMRN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- BTAI
- Stock Information
- Founded
- IMRN 1994
- BTAI 2017
- Country
- IMRN Australia
- BTAI United States
- Employees
- IMRN N/A
- BTAI N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- BTAI Health Care
- Exchange
- IMRN Nasdaq
- BTAI Nasdaq
- Market Cap
- IMRN 10.3M
- BTAI 10.7M
- IPO Year
- IMRN N/A
- BTAI 2018
- Fundamental
- Price
- IMRN $1.71
- BTAI $1.46
- Analyst Decision
- IMRN Strong Buy
- BTAI Buy
- Analyst Count
- IMRN 1
- BTAI 5
- Target Price
- IMRN $5.00
- BTAI $42.60
- AVG Volume (30 Days)
- IMRN 11.8K
- BTAI 97.3K
- Earning Date
- IMRN 05-27-2025
- BTAI 05-12-2025
- Dividend Yield
- IMRN N/A
- BTAI N/A
- EPS Growth
- IMRN N/A
- BTAI N/A
- EPS
- IMRN N/A
- BTAI N/A
- Revenue
- IMRN $4,048,286.00
- BTAI $1,852,000.00
- Revenue This Year
- IMRN N/A
- BTAI $41.00
- Revenue Next Year
- IMRN N/A
- BTAI $197.21
- P/E Ratio
- IMRN N/A
- BTAI N/A
- Revenue Growth
- IMRN 82.90
- BTAI 5.47
- 52 Week Low
- IMRN $1.60
- BTAI $1.29
- 52 Week High
- IMRN $2.87
- BTAI $42.08
- Technical
- Relative Strength Index (RSI)
- IMRN 41.94
- BTAI 37.90
- Support Level
- IMRN $1.87
- BTAI $1.34
- Resistance Level
- IMRN $2.13
- BTAI $1.64
- Average True Range (ATR)
- IMRN 0.15
- BTAI 0.15
- MACD
- IMRN -0.01
- BTAI -0.01
- Stochastic Oscillator
- IMRN 32.71
- BTAI 16.56
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.